PROGRAM OVERVIEW

This program will equip students with solid theoretical and systematic professional knowledge in molecular medicine, biomedical engineering, and related fields. Graduates of this program will have the opportunity to undertake independent scientific research, allowing them to understand the current status and future trends of medicine/biomedical engineering, and write and communicate in English.

MAIN RESEARCH FIELDS:

1. Biomedical information

Apply biomedical engineering techniques and methods to collect, analyze and evaluate health-related biomedical information, establish disease risk prediction and early warning models, explore the underlying reasons of disease pathogenesis, and conduct intervention studies.

2. Cell and tissue engineering

Conduct research on various types of stem cell and bioscaffold materials, and learn how to apply tissue engineering and regeneration technologies to acute and chronic injuries and diseases; conduct research using cell engineering and nanomaterial labeling technologies based on modern gene technology; perform in vivo and in vitro cell tracing and monitoring; and develop new sources of stem cells for research and industrialization amplification technologies, including the development of 3D culture and amplification and bioreactor systems.

3. Systematic Biomedical:

Harness biophysical, biochemical, bioinformatic and systems biology approaches to study human aging and major diseases such as cancer, cardiovascular and cerebrovascular diseases, metabolic diseases, and infectious diseases; use cells, tissues, organs to conduct translational medicine research into human disease mechanisms at multiple levels, and develop personalized and precise diagnostic and treatment approaches.

CORE COURSES

Frontiers in Biomedical Engineering, Biomedical Image Analysis, Lecture on Pattern Recognition Front, Advanced Cell Biology and Disease, Biochemistry and Molecular Biology.

CAREER PROSPECTS

There is a wide spectrum of career paths that can follow from obtaining a PhD in Biomedical Engineering, including but not limited to:

Biomedical Scientist/ResearcherBiomedical scientists and researchers, in both clinical and/or research environments, conduct research that aims to improve human health by carrying out scientific tests to find solutions to medical/clinical problems. They research information that aids in the development of biomedical technology and test products so that they are safe and effective for consumers.

Biomaterials DeveloperBiomedical engineers may develop biomaterials based on either natural living tissue or artificial materials, for use in the human body. Tissue engineering, biomedical implant development, drug delivery and nano implants are all areas that a biomaterials developer may work in. Biomaterials can be used to either repair or replace lost function to the body, or to detect and image disease.

Biomedical Artificial Intelligent (AI) Researcher or Developer AI technology is rewiring many parts of society. How medical/clinical procedures and philosophies will be affected by AI is a thrilling frontier for exploration. A career in this field will involve you not only in science and technology, but also in areas of ethics, finance, and regulation.

Rehabilitation EngineerBiomedical engineers who work in a field dedicated to rehabilitation often work on diverse projects. These can range from mechanical equipment that helps patients regain the ability to walk, to virtual reality systems that aid in limb mobility. Rehabilitation engineers may also create custom solutions based on unique needs or research improvements that can form the basis of a novel rehabilitation technology.

Medical Device/Technology Developer

Medical technology can refer to the hardware and software that help manufacture medical devices, as well as to the technology that is an integral part of those devices. Medical technology professionals with biomedical engineering backgrounds may specialize in bioinstrumentation, or the use of bioelectronic/biomechanical/biochemical instruments to record or transmit physiological information in vivo and/or in vitro.

Consultation

Email:   molmed.hsc@szu.edu.cn                

Email

wuhq@szu.edu.cn

Introduction

Ph.D., Professor, Ph.D. Supervisor. I am a professor in Medicinal Chemistry and Chemical Biology. My lab mainly focuses on the design, synthesis, and evaluation of novel molecules targeting Glutaminyl cyclase, iso-Glutaminyl cyclase and other proteins as potential anti-AD and anti-cancer agents. I pay particular attention in exploring the mechanism underlying the regulation of up-regulated QC and iso-QC in the initiation of AD and caners at the early stage. Research in my lab has been continuously supported by 4 regular grants of the National Natural Science Foundation in China (NSFC), 1 grant of Basic Research Foundation of Guangdong, 4 grants of Basic Research Foundation of Shenzhen, etc since 2015. I have published more than 70 papers in the peer-reviewed professional journals. I am currently mentoring 1 postdoctoral fellows, 2 PhD candidates and 17 MSc candidates.

Email

liuj@szu.edu.cn

Introduction

 Professor Liu is mainly engaged in the study of cardiac function and its regulatory mechanisms under physiological and pathological conditions (cardiac hypertrophy, ischemia/reperfusion injury, etc.). Molecular biology, optical imaging and patch clamp technologies are used in the study to elucidate the mechanisms underlying the pathological remodeling in diseased hearts. She presented the novel roles of the genes such as MG53, Rad and Himf in the regulation of cardiac excitation-contraction coupling and their contributions to the development cardiac arrhythmia and heart failure. She has published papers in journals such as Circ, Circ Res, Hypertension, Basic Res Cardiol as the corresponding author. She has presided over a number of projects of National Natural Science Foundation, Guangdong Natural Science Foundation and Shenzhen Basic Research Project. She also won the first prize of Guangdong Science and Technology Progress, the first prize of Natural Science of the Ministry of Education and the third prize of Guangdong Natural Science and Technology Award, and applied for 3 patents.

Email

ppliew@szu.edu.cn

Introduction

Dr Baohua Liu earned his B.S. degree from Peking University in 1999, and Ph.D. degree in Department of Biochemistry, the University of Hong Kong in 2007. He completed postdoctoral training at the University of Hong Kong and was promoted to Research Assistant Professor in 2011. In 2014, Dr Liu joined Shenzhen University Health Science Center as a Distinguished Professor. During his career, Dr Liu has received awards including Li Ka Shing Prize, the National One Thousand Young Talents Award and the National Excellent Young Researcher Award. His research interests are centered on mechanisms and interventions of aging.

Email

s9zhang@szu.edu.cn

Introduction

Dr Zhang obtained her Ph.D degree in Tsinghua University (major: molecular cell biology)，completed her post-doc training in immunology at University of California, San Diego and then was recruited as associated professor in School of Medicine, Shenzhen University. Dr Zhang’s research interests lie in: Using multidisciplinary approach of molecule cell biology, cell biology, biochemistry, immunology and bioinformatics to investigate the molecular mechanism underlying tumor initiation, metastasis and relapse,  and develop novel small compounds and immunological therapeutics for patients with cancer. To date, Dr. Zhang has developed two novel anti-cancer drugs which are under clinical investigation currently. She had co-authored 25 publications which include three papers published on PNAS and one one Oncogene as first or corresponding author. She had 6 patents and one of them already was commercialized. She has been funded by National Key R&D plan, National Natural Science Foundation of China (NSFC), Shenzhen Peacock Innovation Team Grant and so on. She had been awarded “Excellent Abstract Achievement” by American Society of Hematology (ASH) at 2011.

Email

shu@szu.edu.cn

Introduction

    Dr. Xing-sheng Shu received his B.S. degree from the School of Life Sciences, Peking University in 2008 and his Ph.D. degree from the Department of Clinical Oncology, The Chinese University of Hong Kong in 2012. He is currently an Associate Professor at the School of Medicine, Shenzhen University. Dr. Shu has been working on abnormal epigenetic and transcriptional regulation in cancer and related translational research for cancer therapy. He has published more than 30 SCI papers with more than 1100 citations and an H-index of 18, including more than 10 papers in PNAS, Oncogene, Journal of Pathology, Theranostics and other high impact journals in recent 5 years as corresponding or first author. He also holds two invention patents, and completed many national and provincial research projects. For more information about his research, please refer to the link: https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/.

Email

yingying@szu.edu.cn

Introduction

Prof. Ying Ying (MD, PhD) is the vice president of College of Basic Medicine and also the vice dean of the Department of Physiology at Shenzhen University Health Science Center. She obtained her PhD from University of Heidelberg, Germany, in 2007. Following postdoctoral training at The Chinese University of Hong Kong, she became a Principal Investigator and Professor at School of Medicine, Shenzhen University Health Science Center in China. Her research focuses on epigenetic dysregulation in contribution to the pathogenesis of metabolic and neurodegenerative diseases as well as colorectal cancer. She has presided over the completion of a number of research projects including the National Natural Science Foundation of China. As the corresponding author or first author, she has published over 20 research articles in top journals (i.e. Molecular Neurodegeneration, PNAS, Oncogene, Theranostics, Journal of Pathology, etc.).

Email

wusong@szu.edu.cn

Introduction

Song Wu

MD, Professor, Doctoral Supervisor, President of South China Hospital of Shenzhen University, President of Hospital Management Research Institute of Shenzhen University, Director of Urology Institute of Shenzhen University, Director of Shenzhen Urology Quality Control Center.

Wu’s research is mainly focused on the pathogenetic mechanism of urinary system diseases and develop intelligent diagnosis system for clinical transformation. Wu is also committed to the research of refined management of hospitals and promote health system reformation with the aim to build a smart, high-level and research-oriented hospital.

Wu is the Chief Scientist of National Key R&D Program, National Excellent Young Scientist, Leader of Key Project for National Natural Science Foundation of China, Member of Urology Branch of Chinese Medical Doctor Association, Deputy Director of Precision Medicine and Molecular Diagnosis Branch of Guangdong Medical Association, Chairman of the Shenzhen Medical Association Artificial Intelligence Robot Special Committee, et al. He has won the National May 1st Labor Medal, the Leading Talent in Science and Technology Innovation in Guangdong Province, the Leading Medical Talent in Guangdong Province, and the First Prize of Shenzhen Science and Technology Progress Award.

Email

huiren_tao@163.com

Introduction

  Huiren Tao, Chief Physician, Doctor of Medicine Professor, Doctoral Tutor, Master Tutor of Spine and Osteopathy. He has been engaged in spinal surgery for nearly 30 years and has extensive clinical experience in the diagnosis and treatment of spinal diseases,and completed nearly 10,000 spinal surgeries.

He completed the treatment of the first domestic patient with extremely severe ankylosing spondylitis ("3-on" folding person) and L5 vertebral resection to treat lumbar spondylolisthesis and other operations. He’s one of the doctors that has the largest number of cases and the most effective treatment of spinal deformity all over the country. He is a local-level leading talent in Shenzhen, enjoys special allowances from the Shenzhen government and was awarded the honorary title of Shenzhen's Top Ten Outstanding Contributors to Health in 2019. Undertake 3 National Natural Science Foundation projects and 3 provincial and ministerial fund projects. He has published more than 20 SCI papers in top professional and authoritative journals in the field of spine surgery, such as Spine, and has 14 million yuan in scientific research funding.

Email

Wuxueqing.37@hotmail.com

Introduction

lProfessor, chief surgeon, graduate student advisor, postdoctoral advisor

lShenzhen Overseas High-level Talent (B class), Shenzhen practical type of Clinical Medicine Talent (I class).

Served in several academic societies, including: member of China maternal and child health committee; vice-chairman of reproductive gynecology department of Guangdong provincial association of primary medicine; editorial board of journal of reproductive medicine.

lMain research interests: 1. The effect of early adverse events on the reproductive regulation axis and its mechanism; 2. Molecular mechanism of Epigenetics in gynecological tumors.

lPrincipal Investigator of 2 national natural fund projects and 8 provincial and ministerial-level scientific research projects.

lPublished more than 50 papers in journals such as AJOG, BJOG and so on as the first author and corresponding author.

lthe third prize of the Zhejiang Medical and Health Progress Award; the third prize of the Wenzhou Science and Technology Award.

lTeaching of the undergraduate course “Obstetrics & Gynecology” and the postgraduate course “Advances in Obstetrics & Gynecology”.

lTraining more than 20 graduate students.

Email

doctorgongpeng@szu.edu.cn

Introduction

I am the chief physician and the deputy dean of Shenzhen University General Hospital. I have two excellent teams which focus on clinical and basic cancer research. As the co-author, I wrote a number of clinical guidelines and textbooks in both Chinese and English. Supported by more than ten funds such as the National Natural Science Foundation of China, the Special Scientific Research Fund for Doctoral Programs in Higher Education, and the Provincial Natural Science Foundation, I try to clarify the mechanism of the gastrointestinal tumors and drug resistance. I discovered that the tumor environment plays an important role in tumor development and chemotherapeutic drug resistance. For example, we observed that the levels of macrophages and activated dendritic cells in tumor tissues were significantly higher than that in para-tumor tissues. Macrophages, gamma delta T cells and naive CD4 T cells were independent predictive factors of a poor outcome for pancreatic ductal adenocarcinoma patients. Subsequently, I observed that autophagy and Hippo-YAP1 signaling pathway, two processes, has been reported to regulate the pathophysiology of cancer and the sensitivity to chemotherapy. Bafilomycin A1, an inhibitor of autophagy, could induce caspase-independent cell death via targeting of autophagy and MAPK pathways. In addition, we found tumor suppressor Spred2 interaction with LC3 promotes autophagosome maturation and induces autophagy-dependent cell death. Currently, I have mentored 4 post doctors, 4 PhD candidates, and 30 MSc candidates; we published more than 150 papers.

Email

nieguohui@email.szu.edu.cn

Introduction

Guohui Nie:  The director of Shenzhen Second People’s Hospital, a chief physician and a doctoral supervisor.

Guohui Nie has been engaged in the fundamental  and clinical research on  otolaryngology for more than 37 years, with professional theoretical knowledge and proficient clinical surgery skills. His  research  is focused on fundamental  and clinical research dealing with  hearing and balance problems, early diagnosis and treatment for nasopharyngeal carcinoma. Prof. Nie has undertaken over 20 national, provincial and municipal projects, 3 professional book (editor- in -chief of 1 book, co -editor of 2 books), and 15  licensed patents. Up to now, he has published more than 80 papers at home and abroad and has successively been honoured as the "Shenzhen Model Worker" and the "May-First Labor Medal of Guangdong ".

Currently, Prof. Nie is the member of the Committee of Otolaryngology- Head and Neck Surgery Branch of Chinese Medical Association;the Vice Chairman of Otolaryngology Branch of Guangdong Medical Association;the member of the Standing Committee of Otolaryngology Branch of Guangdong Medical Doctor Association；the Chairman of the Otolaryngology Committee of Shenzhen Medical Association and so on.

Email

shichen@email.szu.edu.cn

Introduction

 Taking the advantage of the latest development of cutting-edge technology , Prof. Shi Chen carry out epigenetic related research, aiming to accurately identify, modify and edit the genome of cells or pathogenic bacteria, identify the defense mechanism of bacterial hosts against viruses and analyze the influence of these epigenetic modifications or genome modifications on the cell life activity or the infection ability of pathogenic bacteria. His studies in this area have published in Nature Catalysis, PNAS (2011,2017,2018), Nature Communications (2014,2019, 2022), Angew Chem Int Ed, FEMS Microbiology Reviews, mBio, Molecular Microbiology, etc. On the other hand, Prof. Chen has published in Autophagy, Nucleic Acids Research, Trends in Cell Biology, Biotechnology Advances, Medicinal Research Reviews, Theranostics, Molecular Neurodegeneration etc as his contribution in neurodegenerative disease research area.

Email

duanl@szu.edu.cn

Introduction

Dr Duan is a full-time researcher and vice director of Central Lab at Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University. After receiving her PhD from Wuhan University, she was a postdoctoral fellow in the Medical Center of Groningen University and Sun Yat-Sen University, then a visiting scholar in the department of Molecular Biology at the Fukuoka Dental College.

Her main research interests are the nanoparticle delivery for musculoskeletal system disease treatment. Dr Duan has received many awards such as Third prize of Chinese medical science (2017). She received many research grants, including National Natural Science Foundation of China and European Orthodontic Society. Her total research funding was more than RMB¥12,000,000. She has published 50 peer-reviewed articles, several books and book chapters.

Email

wlliu@szu.edu.cn

Introduction

Liu Wenlan, MD, PhD, Professor, Shenzhen overseas high-level Class B talent, the Director of the Central Laboratory of the First Affiliated Hospital of Shenzhen University/ Shenzhen Second People's Hospital, and the Director for Basic Research of  Neurosurgery Department. Committee member of Chinese Medical Association Neural Homeostasis and Endocrine Branch, Committee member of China Society of Microcirculation Neurological Protection and Rehabilitation Committee, Standing committee member of Brain Development and Encephalopathy Prevention and Control Society, Standing committee member of Guangdong Medical Association of Laboratory Construction and Management Branch, Chair of Shenzhen Medical Association Experimental Medical Professional Committee. My research has been focused on the dynamic evolution of ischemic penumbra and blood brain barrier injury as well as their association with reperfusion therapy-associated with hemorrhagic transformation in the super-early stage of ischemic stroke. I have been a well-funded principle in the past 13 years and my research has been supported by 25 research grants from  National Health Center, American Heart Association (AHA), the National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation, and  Shenzhen Municipal Science and Technology Innovation Commission. I have served as a grant reviewer for  AHA, National Natural Science Foundation of China, Guangdong Natural Science Foundation and Shenzhen Municipal Science and Technology Innovation Commission. I have published more than 100 research papers in peer-reviewer journals including J Neurosci, Stroke, Aging Cell, Neurobiol Dis, Exp Neurol, J Neurochem, Mol Neurobiol, Front Mol Neurosci and so on. I have been authorized 4 US invention patents, 7 Chinese utility model patents, and 2 Chinese invention patents.    

Email

Lzssc@email.szu.edu.cn

Introduction

Dr Li is currently a professor at the School of Medical Sciences, the University of Shenzhen. He graduated from the Southwest Normal University with a Bachelor of Science in biology, and obtained his Master of Science from the School of Biology of Wuhan University. Zesong Li received a Ph.D. from the School of Bioengineering of Chongqing University. After his working experience relevant to genomics of urogenital tumors with high-through sequencing in Shenzhen PKU-HKUST Medical Center, he joined the First Affiliated Hospital of Shenzhen University in 2011, where he directed his research to the molecular biology and proteomics of urogenital tumors. His research interests include marker screening and early detection of urogenital tumors by proximity barcoding assay, and identification of novel targets and signaling pathways in cancer pathogenesis and metastasis using various rodent models in vivo. Dr. Li served as the director of Shenzhen Key Laboratory of Genitourinary Tumor in 2012, and Executive Deputy Director of Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors in 2017. He has published 70 international journal articles with a majority of studies related to cancer research, including leading-authored articles in Nature genetics. He has raised a total of over 10 million Yuan in external competitive grant funding, including 3 general projects of NSFC. Moreover, he has been honored with many science and technology awards.

Email

Xuxundi@126.com

Introduction

He graduated from Medical Department of Hunan Medical University in 1989.After graduation,he was assigned to the General Surgery Department of the Second Affiliated Hospital of Hunan Medical University.In 1998, he went to study in the Second Surgery Department of the Medical Department of Kyoto University in Japan.In 2004, he received a medical doctor's degree in the the Medical Department of Osaka University.He learned from Professor Yu Mentian,as a former vice president and as a former president of the Japanese Surgical Society and the Japanese Cancer Society. He is good at diagnosis, treatment and research of hepatobiliary and pancreatic surgical diseases. He took the lead in carrying out highly difficult and complex operations such as radical resection of complex hilar cholangiocarcinoma (including portal vein resection and type IV tumor resection) and extended radical resection of pancreatic cancer.He has achieved good results of new technology in the treatment of acute severe pancreatitis with regional arterial infusion.

Email

doctorzhanghua@163.com

Introduction

Doctor of medicine, professor, chief physician, Doctoral supervisor and postdoctoral co-supervisor of Shenzhen University, enjoy the "Special Allowance of the State Council", " National millions of talents", and Shenzhen local-level talent. Director of Brain Center, and Neurosurgery and academic leader of Union Shenzhen Hospital, Huazhong University of Science and Technology. The Youth Committee of the Neurosurgery Branch of the Chinese Medical Association, the Standing Committee of the National Skull Base Surgery Branch of the European and American Alumni Association.

Presided over two the National Natural Science Foundation, and eight the Provincial and Ministerial Fund, one major project of Shenzhen Science and Technology Innovation Commission, and published more than 60 articles, reviews and treatises. Has been the province departmental level scientific and technological progress second prize of 2, and third prize of 1.

Be good at：AI and Brain Tumors

Email

qiuyw1201@gmail.com

Introduction

Male, medical doctor, tutor of Ph.D.. His research focuses on functional MRI and radiomics. He had achieved 2 national scientific research project  and 3  provincial  scientific research projects. He had published more than 40 academic papers as the first author or corresponding author with IF up to 160 points, of which 36 were published in SCI periodicals such as “Radiology, NeuroImage, Human Brain Mapping, Radiotherapy and Oncology, European Radiology, AJNR, JMRI and Addiction Biology” , ect.

Email

luodixian_2@163.com

Introduction

Dixian Luo, the doctor of medicine, level-2 researcher, doctoral supervisor, the special allowance provided by the state council, and the winner of the Hunan Provincial Outstanding Youth Fund. He is currently the director of the Laboratory Medicine Center of the Union Medical College Shenzhen Hospital, Huazhong University of Science and Technology, the vice chairman of the Youth Committee of the Chinese Anti-Cancer Association Tumor Marking Special Committee. The main research direction is the development of tumor markers and molecular mechanism research, the development and application of new tumor molecular diagnosis technology, etc. He has undertaken more than ten scientific research projects for the National Natural Science Foundation of China, the provincial and ministerial levels and published more than 40 SCI research papers. Furthermore, he has authored six monographs and authorized many national patents.

Email

hongxiangchen@hotmail.com

Introduction

Third-level professor, chief physician, and doctoral supervisor. Postdoctoral fellow in Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, and visiting scholar at Kyushu University in Japan. He is currently the executive vice president of Huazhong University of Science and Technology Union Shenzhen Hospital.

Young vice chairmen of the Dermatology and Allergy Branches of the Chinese Medical Doctor Association have held more than 10 academic positions. He presided over 6 projects of the National Natural Science Foundation of China and more than 10 projects including the New Teacher Fund of the Ministry of Education. In 2011, he became the sole winner of the Bill & Melinda-Gates Fund in China (medical projects). More than 100 academic papers have been published, and more than 60 papers have been included in SCI.

He was selected as "Outstanding Young and Middle-aged Physician in Chinese Dermatology", "Chinese Health Communication Ambassador", "Outstanding Communist Party Member in Fighting against the New Coronary Epidemic", 2021 Future Medical Top 100-Weilan Award "Annual Innovative Hospital Director", etc.

Email

junwupro@126.com

Introduction

Jun Wu, Professor, director of the Department of Burns and Plastic Surgery, The First Affiliated Hospital of Shenzhen University. The past president of Chinese Burn Association, the past president of Chinese Burn Rehabilitation Association, the president of Chinese Wound Repair Association, the past executive member of International Society for Burn Injury, the representative of east Asia of ISBI, etc. He is the editor-in-chief of Burns and Trauma, and the executive editor-in-chief of Chinese Burn and Wound Journal Main academic contributions: He led rehabilitation and charity processes into nation-wide Burn Units, established accreditation and certification practices, and co-created national prevention projects. He founded a world-known journal Burns and Trauma, and is active in international academic exchange. He invented low-cost biomaterial dressings that promoted Chinese burn care. Moreover, he is very active and successful in translational medicine: more than 7 patents have been transferred to investors and companies.

Email

hequnzou@hotmail.com

Introduction

Hequn Zou, Executive Dean of South China Hospital of Shenzhen University.  Professor of Nephrology, Chief Doctor, Tutor of Doctor Candidates. He has undertaken more than 30 scientific research projects at home and abroad, , including more than 10 national and international cooperative scientific research projects, with a total funding of more than 40 million yuan. More than 300 papers were published, including more than 70 SCI papers (3 in JCR Zone 1 and 9 in JCR Zone 2). Main research directions: Pathogenesis and prevention of tubulointerstitial nephropathy,Pathogenesis and prevention of chronic renal allograft failure, Study on complications of hemodialysis and clinical techniques of plasma purification, Study on the pathogenesis, prevention and treatment of immune complex associated glomerulonephritis, Early diagnosis and early intervention of diabetic nephropathy.

Email

qiwendeng@hotmail.com

Introduction

Deng Qiwen, M.D., Chief Physician, President of Huazhong University of Science and Technology Union Shenzhen Hospital, Leader of the Department of Infectious Diseases, Director of the Key Laboratory of Endogenous Infection Diagnosis and Treatment of the Shenzhen Science and Technology Innovation Commission, Ph.D. supervisor and Postdoc advisor of Shenzhen University. He has served in 11 national, provincial, and municipal microecology and infection-related professional societies, and has received 15 national and provincial grants with a funding amount of over 4 million RMB. More than 50 SCI articles and 5 related patents were published and obtained. Dr. Deng has long been engaged in the diagnosis and treatment of infectious diseases and the prevention and control of hospital infections and is a well-known domestic expert in the diagnosis and treatment of difficult and critical infectious diseases, the prevention and control of hospital infections, and the research of antimicrobial infections. His current research interests include (1) new technologies for non-invasive diagnosis and treatment of bacterial pathogenic infections; (2) screening, identification  and delivery of new anti-infective drugs and their mechanisms; (3) research on microbial drug resistance and pathogenesis; (4) research on the interrelationship between microecology and disease.

Email

gracelfu@szu.edu.cn

Introduction

Personal Statement (ORCID 0000-0003-2643-6278):

My research goal is to understand the mechanisms of initiation and progression of gastrointestinal (GI) cancers and identify new therapeutic targets for cancer treatment. 

The research in my laboratory has been continuously supported by the National Natural Science Foundation in China (NSFC), General Research Fund (GRF) of Hong Kong, and grants from the Shenzhen Science and Technology Innovation Department since 2014.  I have published 88 papers in the cancer research field in various peer-reviewed international journals (H-Index 37), including Gut, Hepatology, PNAS, Cancer Research. I have obtained 6 China patents and have been awarded the Overseas High-level Talents and Pengcheng Scholar Distinguish Professorship by the Shenzhen Government. I am currently mentoring one postdoctoral fellow, two PhD and five MSc candidates.

Research Interests:

•Prognostic and predictive tumor biomarker discovery and development;

•Molecular mechanism of the immunosuppressive tumor microenvironment;                                                                       

•Tumor stroma and cancer stem cell-targeted novel immunotherapeutic strategies.

Email

Huangcibo1208@139.com

Introduction

Professor Cibo Huang, master of rheumatology and immunology, chief physician, doctoral supervisor, grade II professor, vice president of South China Hospital, Shenzhen University, and Chairman-designate of Internal Medicine Branch of Chinese Medical Association. He is mainly engaged in basic and clinical research in rheumatology, including basic research on osteoarthritis, Sjogren syndrome and immunosorbent technology for rheumatic immune diseases such as systemic scleroderma, systemic vasculitis, lupus erythematosus and rheumatoid arthritis. His main research interests include: immunopurification technology for immune-related diseases and development of immunosorbent column; research on the pathogenesis of osteoarthritis and intra-articular injection of chondrocytes transformed from stem cells; research on EDTA treatment for various fibrotic diseases; research on medication guidance for geriatric multi-organ diseases and diagnosis and treatment of multi-organ failure; research on biological agents treatment for arthritis and autoimmune diseases.

Email

pony8980@163.com

Introduction

Professor of urology and Vice President of Translational Medical College, The First Affiliated Hospital of Shenzhen University. Chief scientist of the National Key R&D Program. Deputy Director of Guangdong Key Laboratory of Urogenital Neoplasms and Synthetic Biology, Director of Shenzhen Key Laboratory of Medical Gene Reprogramming Technology. Dr. Huang is mainly engaged in the research of precision medicine and synthetic biology in cancer. In recent years, Professor Huang's team took the high incidence of bladder cancer in China as a model to combine the engineering concept with tumor research early, and systematically discovered a number of effective targets for phenotype recognition and control of bladder cancer cells. The synthesis and characterization of bladder cancer specific gene switch elements were completed. An artificial gene circuit that can simultaneously sense multilevel signals is constructed to realize the specific differentiation of tumor cells and the intelligent recognition and artificial regulation of tumor signal network, and further understand the pathogenesis of tumor. Organoid culture methods were established for more than 10 cancer species, including upper urothelial cancer, bladder cancer, kidney cancer, prostate cancer, lung cancer and thyroid cancer, and related drug screening and evaluation studies were carried out. Some cancer species were reported for the first time in the world, and a variety of application exploration was carried out in tumor precision medicine and drug research and development. He has published more than 100 academic papers in journals such as Nature Methods, Nature Communications, Advance science, Genome Biology, etc. He has been granted 14 national invention patents and won the Chinese Medicine Award (First Accomplisher). Shenzhen Natural Science Award (First Accomplisher).

Email

jiangyy@sz.tsinghua.edu.cn

Introduction

Deputy director of State Key Laboratory of Chemical Oncogenomics. Director of Guangdong Province Key Laboratory of Chemical Biology.

Research Fields:

1. The design, synthesis and bioactivity study on small molecular inhibitors targeting tumor-related pathways.

2. Signal pathways and networks in tumor cells regulated by pokemon, and biomarker discovery.

3. Metabolic and proteomics study on tumor and pharmaceutical analysis.

4. Chemical modification of nucleosides and its application in antitumor gene drugs.

5. Fluorescence-based biosensors and molecular probes targeting cancer diagnosis and drug mechanism studies.

Email

18804511716@163.com

Introduction

  Professor, doctoral supervisor, American clinical medical doctor, expert and scholar in the field of tumor molecular imaging. Prof. Li has worked at National Institutes of Health (NIH) (the most influential national research institutions in the world), National Institute of Biomedical Imaging and Bioengineering (NIBIB). Dr. Li had clinical work visits to world-renowned universities and hospitals. She had been on the editorial board of recommended textbooks for universities and graduate students, compiled professional works, participated in international cooperation and completed more than ten national top scientific research projects. She has published tens of research works, and is a reviewer of many English magazines. And she is the member of the World Molecular Imaging Congress (WMIS) and Radiological Society of North America (RSNA). In 2011, 2016 and 2017, she won prizes at WMIC and HIVR4P.

Main research areas: development of novel molecular imaging contrast agents; ultra-sensitive method for detection of multiple biomarkers; building smart nano-platforms for targeted delivery of drugs and genes; clinical transformation of molecular imaging probe; development and clinical transformation of nanomaterials integrated with diagnosis and treatment.

英文名

Nan Liu

Email

13688869875@163.com

Introduction

Prof/Dr. Nan Liu, M. D., received doctorate degree from Academy of Military Medical Science, Beijing, China in 2009, mainly engaged in the development of environment and health. He has served the army for almost 15 years in 2003-2017. Now, he is in charge of Department of Science and Education and Institute of Environment and Health in South China Hospital, Shenzhen University.

His research areas are including: molecular network regulation mechanism of chronic injury induced by combined exposure of environmental pollutants, key technologies for monitoring and assessment of environmental and health risk factors and rapid determination of chemical pollutants, etc. He has published 80 papers including 40 with the first/corresponding authorship and taken charge of a variety of the Natural Science Foundation of China (4 items), the National High Technology Research and Development Program of China.

He has rewarded the Youth of Science and Technology Award of Chinese Society of Toxicology in China and the first "Innovation Strategic Talent Project" talents in Academy of Military Medical Sciences.

Email

peixinhai@szu.edu.cn

Introduction

Dr. Pei is interested in using mouse genetic approaches to investigating the molecular and cellular basis of tumor suppression. Though time consuming and complicated, utilizing such methodology is a necessary step toward the goal. Dr. Pei generated 5 strains of knockout mice and characterized 45 different mouse mutants for various cell cycle inhibitors and tumor suppressors, and demonstrated their functions in the control of stem/progenitor cells and tumorigenesis of multiple tissues. Dr. Pei discovered that p18^INK4c is a downstream target of GATA3 and restrains mammary luminal progenitor proliferation and tumorigenesis (Pei XH, Cancer Cell, 2009).  As a tenure track assistant and associate professor at the University of Miami, Dr. Pei published 17 research papers. He discovered that deletion of Brca1 causes luminal-to-basal mammary tumor transformation (Bai F, Oncogene, 2013). BRCA1 suppresses EMT during mammary and tumor development (Bai F, Cancer Res., 2014). Since Oct 2018, Dr. Pei has been moving to China and working as a full professor at the Shenzhen University School of Basic Medical Sciences. In addition to the abovementioned areas, he is also very interested in 1) how LncRNA controls cancer development and progression; 2) how cell cycle inhibitors and transcription factors control cochlea hair cells in hearing loss and tubular cells in polycystic kidney disease. Recently, he discovered that loss of function of BRCA1 promotes EMT in mammary tumors through activation of TGFβR2 signaling pathway (Cell Death & Disease, 2022) and loss of function of GATA3 induces basal-like mammary tumors (Theranostics, 2022).

Email

suwen@szu.edu.cn

Introduction

Dr.Su has been focusing on the field “lipid droplet, lipid droplet proteins, dysregulation of lipid metabolism and metabolic diseases” for a long time with a series work. She purified and established human liver LD-associated proteome and identified an array of proteins differentially expressed in human NALFD. She demonstrated a liver-specific LD protein 17βHSD13 as a pathogenic factor and drug target of NAFLD (2014, 111 (31):11437, PNAS). Since joining Shenzhen University, she carried out several related studies, including: (1) Function study of 17β-HSD13 by using various hsd17b13 (the gene codes 17β-HSD13) genetic edited mice and biochemistry methods; (2) Elucidate the mechanism of lipid dysregulation in acute and chronic liver diseases; (3) Screen of lead compounds that targets 17β-HSD13, FXR, LXR for NAFLD treatment. Dr Su’s original research about 17β-HSD13 provides a potential link between LD proteins and NAFLD, and has been cited by more than 120 papers including papers on NEJM, hepatology, journal of hepatology and so on. She found over-expression of 17β-HSD13 in vivo and in vitro increases size and accumulation of lipid droplets in hepatocytes, which possible mechanism is through enhancement of lipogenesis and maturation of SREBP-1c. Her subsequent work demonstrated 17β-HSD13 was regulated by LXRα agonist T0901317 via a SREBP-1c dependent mechanism (2017, 312(4), Am J Physiol Endocrinol Metab.;2018, 67(supplement 1), Diabetes). She proposed the possible regulation mechanism of 17β-HSD13 and SREBP-1c, and suggested 17β-HSD13 as a potent NASH target (2019, 489:119-125, Mol Cell Enocrinol.). She has 2 patents on 17β-HSD13 and NAFLD drug target. She now successfully constructed 17β-HSD13 liverspecific transgenic, knockout, liver-specific knockout, and two key amino site mutant mice lines, and also a various of HSD17B13 associated plasmid. Her next 5 year-plan include: 1. Define the metabolic phenotypes of those genetically engineered mice; 2. Determine the pathophysiological role of 17βHSD13 during different stages of NAFLD from benign steatosis, NASH to HCC via challenging highfat diet (short term and long term), MCD, and FPC models; 3. Characterize the biological function of 17β-HSD13 by using biochemical, lipidomic, and metabolomic approaches; 4. Study the role 17β-HSD13 in regulating LD generation, growth, fuse, and degradation and the post-translational modification of 17βHSD13. In terms of paper publication and academic effect. Dr.Su’s h-index is 17.

Email

Lei.wang@szu.edu.cn

Introduction

The focus of my research is on exploring how immunotherapy impacts the dynamic of immune responses in patients with solid tumors, with the goal of understanding the immunoregulatory mechanisms of host systemic immunity and developing novel prognostic/predictive biomarkers. We utilize state-of-the-art technologies – such as single-cell multiomics, quantitative spatial image analysis, high-parameter flow cytometry and advancebioinformatics – to dissect the complex interplay between immune cells and cancer cells within tumor microenvironment and host immune macroenvironment including tumor-draining lymph nodes and peripheral blood.

Email

xn100@szu.edu.cn

Introduction

Ni Xie, doctor of oncology and management, researcher, doctoral supervisor, professor, has been engaged in the molecular mechanism research of tumor development, recurrence, metastasis and drug resistance for a long time. At present, she is the chief of science and education department and director of biobank of Shenzhen Second People's Hospital, doctoral supervisor of Guangdong Medical University, master supervisor of Shenzhen University, Guangzhou Medical University and Nanhua University.

Member of the information group of the professional committee of clinical data and sample resource base of China Research Hospital Association, member of the professional committee of clinical data and sample resource base of China Research Hospital Association, member of the Standing Committee of the special committee of viral oncology of China Research Hospital Association, member of the tumor marker Committee of China Anti-Cancer Association, and standing member of the precision medicine and molecular diagnostics branch of Guangdong Medical Association Standing member of the professional committee of integration of Chinese and Western medicine of Guangdong Academy of traditional Chinese Medicine. Guangdong Provincial Natural Science Foundation peer review expert, Shenzhen Science and technology review expert, director of Shenzhen immune cell therapy Engineering Laboratory, deputy director of Shenzhen Key Laboratory of nanoenzyme oncology.

She serves as the editorial board member of "Cancer Management and Research" and "International Journal of Oncology". She published more than 40 high-quality academic papers in international journals such as Nat. Commun, Theranostics, and Obtained 6 national invention patents. She has presided over more than 20 national, provincial and municipal projects. In the past 5 years, she has received more than 20 million yuan in project funding, trained 15 postgraduates, won the second prize of science and technology of the Chinese Society of Integrated Chinese and Western Medicine, and won the Guangdong Science and Technology Progress Award.

Email

liangyeszu@163.com

Introduction

Liang Ye, Associate professor and independent PI of Shenzhen University Health Science Center. "Pearl River Talent Program" young top talents, Shenzhen overseas high-level "Peacock Program" category B talents. Our findings have been published in Nat. Immunol, Nat. Rev. Immunol, J. Virol, J. Immunol, Theranostics, and other journals, and have been widely cited by Nature Immunology and eLife journals. Our group was interested in the immunoregulatory mechanism of host defense against viral infection. We developed a variety of gene-deficient mice and conditional knockout mice to investigate the immunoregulatory mechanism of the interferon system (type I and type III IFNs) against viral infection, the effects of epigenetic modification on virus invasion and escapism host immunity, and the exploration of new viral vaccines and neutralizing nanobodies to combat viral infectious diseases.

Email

yuzhijiansmu@163.com；

Introduction

Dr. Yu Zhijian, Chief Physician, Doctor of Medicine, Ph.D. supervisor of Shenzhen University, Chief Physician, Director of the Key Laboratory of Nosocomial Infection, Director of the Department of Infectious Diseases of Huazhong University of Science and Technology Union Shenzhen Hospital. He has long been engaged in the diagnosis and treatment of infectious diseases and hospital infection prevention and control and has extensive clinical experience in the field of emerging infectious diseases and difficult febrile diseases. Since 2019, 23 international SCI papers (first or corresponding author) have been published, of which 15 have impact factor >5 and 2 >10. He has received 13 national, provincial and other grants with about 4 million RMB. In addition, he has served in 7 national, provincial and municipal microecology and infection-related societies. His research interests include (1) the screening, identification, optimization and delivery of anti-infective drugs and their mechanisms; (2) molecular mechanisms of biofilm development; (3) study of bacterial resistance mechanisms and evolutionary characteristics of antibiotic resistance; (4) development of novel approaches for nosocomial infection control; (5) applying proteomics and metabolomics and other related multi-omics technologies to help study the antibacterial mechanism of drugs.